April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Statistical Arbiters of Clinical Trial Success in Dry Eye
Author Affiliations & Notes
  • Benjamin D Sullivan
    TearLab Corp, San Diego, CA
  • Footnotes
    Commercial Relationships Benjamin Sullivan, TearLab, Corp (E), TearLab, Corp (I), TearLab, Corp (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1974. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benjamin D Sullivan; Statistical Arbiters of Clinical Trial Success in Dry Eye. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1974.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The purpose of this study was to provide a formal statistical basis to understand clinical trial outcomes when using various biomarkers in dry eye disease.

Methods: The model used the TearLab CVS patient database of bilateral tear osmolarity, corneal/conjunctival staining, TBUT, Schirmers, MGD, and OSDI measures. Dry eye subjects were randomized into two groups of N=50, with resulting composite severities of 0.40 and 0.41. A target severity was chosen for placebo (0.36), low effect (0.30), and high effect (0.27) compounds. To estimate therapeutic efficacy, patients with either a uniform or Gaussian probability centered around the target severity were randomly selected to populate treatment groups. The use of composite severity as a coordinate provided an unbiased model free from assumptions on any specific biomarker. Results were compared to a retrospective analysis of clinical trial data to test the model performance.

Results: The uniform low effect model returned significant reductions compared to placebo in osmolarity (309.3 vs. 317.9 mOsm/L, p < 0.005) and severity (0.32 vs 0.37, p < 0.017), and almost achieved significance in OSDI (15.6 vs. 24.4, p < 0.057). TBUT, staining, and MGD grading were not significant (p = 0.314, 0.345, 0.134 respectively). The uniform high effect model demonstrated significant reductions across all signs (p < 0.001 for all). However, when selections were repeated 50 times for each effect size, the average p value across all signs was 0.39 for the low effect and 0.15 for the high effect, with none of the signs averaging < 0.05, even though in individual trials each marker would occasionally reach significance. Of particular interest, the primary determinant of clinical trial success was the homogeneity of response. Reducing the standard deviation of the Gaussian model resulted in consistent significance in both low and high effect sizes. The retrospective analysis of the literature suggests that this model partly explains the superiority of tear osmolarity as a marker for therapy, as osmolarity was the only sign to reduce its variability (e.g., improve homogeneity) following therapy in a variety of trials.

Conclusions: The key driver in clinical trial success is the homogeneity of the patient response, suggesting that qualifying patients with a single etiology and relying upon biomarkers that reduce variability following treatment is paramount.

Keywords: 486 cornea: tears/tear film/dry eye • 459 clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • 479 cornea: clinical science  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.